日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Adagene, Sanofi ink $2.5b deal for cancer solutions

By ZHOU WENTING in Shanghai | China Daily | Updated: 2022-03-03 09:48
Share
Share - WeChat
Visitors gather at Sanofi's booth during the fourth China International Import Expo in Shanghai in November. [Provided to China Daily]

China's Adagene Inc, a Nasdaq-listed innovative biopharmaceutical company focusing on discovery and development of antibody-based novel cancer immunotherapy, announced collaboration and inked an exclusive license agreement with Sanofi for $2.5 billion on Wednesday, the company said.

According to the deal, Adagene will authorize its core technology to Sanofi and help it create new medicines. The potential transaction value to be seen through such cooperation between the domestic biopharmaceutical enterprise with its partner hit a record in its field, said industry insiders.

"Original biopharmaceutical developments from China are attracting rising international attention, and new drugs that can truly solve unmet clinical medical needs will always be the pursuit of innovation," Luo Peizhi, co-founder and CEO of Adagene, said during an exclusive interview with China Daily.

The agreement said Adagene, founded in Suzhou, Jiangsu province in 2012, will be responsible for early-stage research activities to develop versions of Sanofi candidate antibodies, using Adagene's proprietary technology. Sanofi will be responsible for later-stage research and clinical, product development and commercialization activities.

"We look forward to working with Adagene to design antibodies that can help us bring transformative new medicines to people living with cancer," said Valeria Fantin, global head of oncology research at Sanofi.

"Adagene's antibody platform is expected to help us precisely target established, but poorly addressed oncology mechanisms with best-in-class medicines," she said.

Luo said the proprietary technology is a precision antibody masking platform designed to enable the antibody to bind to its target specifically only after conditional activation of the antibody in target tissues.

By engineering and developing therapeutic antibody candidates to selectively activate in the tumor microenvironment, the platform is designed to improve safety and tolerability of antibody therapeutics while maintaining clinical activity.

"This core technology from us has been proven through extensive preclinical and clinical data. So far, a very limited number of companies can develop and apply such technology with clinically validated efficacy," Luo said.

Raymond Tam, chief financial officer of Adagene, said the company's gains from the authorization are fairly competitive in terms of both upfront fees and total potential milestone payments. The company will also get tiered royalties on future global net sales, he said.

Industry observers said that China is expected to enter the world's first echelon in new drug research and development within the next decade, and multinational pharmaceutical giants are deepening collaboration with local players in recent years.

The United States Food and Drug Administration on Monday approved CAR-T, a tumor immunotherapy, to treat adults with multiple myeloma. The medicine was a potentially best-in-class innovative tumor drug developed by Nanjing-based Legend Biotech. Later, Janssen Pharmaceutical joined in its development.

Last month, US-based Eli Lilly, which reached deals with more than 10 Chinese pharmaceutical enterprises in clinical development projects among others over the past decade, established its China innovation incubation platform in Shanghai's Zhangjiang High-Tech Park to join hands with more partners to create original medications from local sources.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 精品免费| 亚洲精品成人 | 欧美黄色免费网站 | 亚洲欧美日韩一级特黄在线 | 天天做天天爱天天影视综合 | 99re在线| 三级黄色免费观看 | 一级一片在线播放在线观看 | 国产精品美女久久久久久免费 | 久操伊人 | 国产精品视频播放 | 欧美全黄 | 99精品电影 | 小草社区影院 | 精品一区二区三区18 | 一级毛片丰满 出奶水 | 妈妈的朋友酷客影响 | 四虎海外| 天天艹夜夜艹 | 亚洲午夜精品A片久久不卡蜜桃 | 自拍 第一页 | 午夜小视频网站 | 国产精品成人在线播放 | 日本久久精品视频 | 成人影院欧美大片免费看 | 贺鹏个人资料 | 午夜亚洲 | 亚洲精品久久久久久中文字幕小说 | 成人免费毛片aaaaaa片 | 国产chinese视频在线观看 | 国产精品1区 | 偷偷狠狠的日日高清完整视频 | 国产午夜免费视频片夜色 | 999精品视频 | 亚洲国产第一区 | 国产精品岛国久久久久久久 | 二区在线视频 | 一区二区三区在线 | 网站 | 久久久一区二区三区精品 | 桥本有菜免费av一区二区三区 | 欧美一级二级三级视频 |